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ANP did not result in significant changes. These favorable renal effects
were associated increases in both plasma cGMP and urinary cGMP ex-
cretion, which were similar with BNP and Uro, however was unchanged
with ANP. This study demonstrates the superiority of BNP to Uro and
ANP in enhancing renal function in severe experimental CHF. These
studies also support the conclusion that with CHF, renal resistance to
natriuretic peptides in increasing rank order is BNP< Uro< ANP. These
results may have clinical implications when considering the therapeutic
efficacy of these peptides in the management of overt CHF.
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Chronic heart failure (CHF) is characterized both by ventricular and
vascular remodeling. Osteopontin (OP) is an extracellular matrix pro-
tein, that might have a role as a marker of ventricular remodelling, its
expression being increased in myocardial tissue of CHF patients from
biopsies. Adrenomedullin (AM), a potent vasodilator peptide secreted
by endothelial cells, and endothelin (ET), a substance with long-acting
vasocostrictor action, might express the paracrine vasomotor response to
CHF progression.
In the present study, we measured plasma levels of AM, OP and of big-
endothelin-1 (Big-ET-1), the ET-1 precursor, whose circulating levels
may reflect ET-1 overproduction more accurately than ET-1 itself. We
studied 125 patients affected by CHF of idiopatic or post-ischemic origin,
(ejection fraction: 33.6 ± 0.87%, mean ± SEM), 82 in NYHA class I-II
and 43 in III-IV class and 20 healthy subjects, as control group.
Plasma AM levels were determined by a radioimmunoassay while Big-
ET-1 and OP plasma levels were determined with ELISA methods.
The mean (± SEM) plasma levels of AM in control subjects were
13.8±1.05 pmol/l and in patients with CHF showed tendency to be in-
creased in those in functional class I-II (18.8±1.12 pmol/l) and were
significantly increased in those in NYHA class III-IV (21.4±2.3 pmol/l,
p=0.015). Plasma levels of Big-ET-1 in control subjects were 1.4±0.12
fmol/l, in patients with CHF were unaffected in those in functional class
I-II (1.4±0.08 fmol/l) but significantly increased in those in NYHA
class III-IV (2.0±0.22 fmol/l, p=0.047). Plasma levels of OP in nor-
mal subjects were 238.0±16.0 ng/ml and were significantly increased
in those in NYHA classes I-II (368.2±21.9 ng/ml, p<0.0001) and III-
IV(485.6±70.5 ng/ml, p<0.0001). A significant correlation between
plasma levels of AM and Big-ET-1 (r=0.5, p<0.01) was observed. These
results indicate that plasma levels of AM, OP and Big-ET-1 are elevated
in CHF, with an increase proportional with the severity of disease, sug-
gesting a role of these substances as markers of endothelial vasomotor
response to CHF progression and of myocardial remodeling, respectively.
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Since first reports demonstrated interactions between the natriuretic pep-
tide (NPS) and renin-angiotensin system (RAS), our experiments should
clarify whether cardiac BNP is regulated in mice genetically altered
for components of the RAS. The study was carried out in hypoten-
sive AT1- and angiotensinogen (ANG)-, in normotensive AT2-knockout
mice, and in hypertensive animals overexpressing ANG and their own
wildtypes. Ventricular BNP expression was analyzed by RNase protec-
tion assay (n=6). Cardiac fibrosis was visualized by Sirius red staining.
While ANG overexpression increases cardiac BNP-mRNA expression
(1035±210 vs. wildtype: 405±95 in PSL/mm2, P< 0.01), its deficiency
had no influence. Both AT1- and AT2-knockouts showed significantly de-
creased BNP-mRNA concentrations (AT1: 21±6 vs. wildtype: 139±28
in PSL/mm2, P< 0.001; AT2: 8±2 vs. 19±3 in PSL/mm2, P< 0.05).
These alterations correlate to reduced cardiac fibrosis in AT2-deficient
animals, but not in ANG knockouts. Increased BNP-mRNA levels in
hypertensive ANG-overexpressing mice and decreased BNP in hypoten-
sive AT1-deficient animals indicate that this mRNA expression is blood
pressure dependent. However, the observed alterations of fibrosis and
the unchanged BNP in hypotensive ANG knockouts and impaired BNP-
mRNA expression in normotensive AT2-deficient mice demonstrate a
direct interaction of the RAS and NPS that is fibrosis but not blood pres-
sure dependent.
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Increased circulating adrenomedullin (AM) concentration has been re-
ported in human congestive heart failure (HF) suggesting that plasma
AM, as other circulating peptides, is a marker for cardiac dysfunction.
It was suggested that the dysfunctioning myocardium secretes AM con-
tributing to its elevation, as a probable compensatory mechanism. How-
ever, no significant relation has been demonstrated so far between left
ventricular (LV) systolic function and circulating AM in patients (pts).
Aim of the present study was to assess, in pts with idiopathic cardiomy-
opathy (ICM), the possible relationship between circulating AM concen-
tration and LV contractile state as non-invasively assessed by the rate of
pressure rise (RPR) from a mitral regurgitation velocity curve at Echo-
Doppler. This parameter correlates with invasively derived peak LV dP/dt
and is an independent prognostic indicator in HF.
Forty-four ICM pts (31 males, mean age 63 years, LVEF 32.0 ± 8.0,
mean ± SD, angiographically normal coronary arteries in all) underwent
a complete Echo-Doppler examination within 1 week of circulating AM
measurement. Five pts were in NYHA Class I, 23 in NYHA Class II,
16 in NYHA Class III. RPR was calculated by measuring the mean rate
of pressure rise of the mitral regurgitation jet between 1 and 3 m/s on 5
consecutive beats. LVEF was obtained by the modified Simpson’s rule.
Plasma AM levels were measured in HF pts and in 20 control subjects by
radioimmunoassay after solid phase extraction on Sep-pak C18 columns.
The extraction recovery was evaluated by adding 125-I-AM to plasma
samples (n=6) and resulted about 66%. Sensitivity was about 16 pg/ml
and intra-assay and inter- assay variability resulted about 5% and 16%,
respectively. The plasma concentrations of AM in HF pts were higher
than in controls (18.0 ± 1.4 vs. 13.8 ± 1,0 pmol/l, mean ± SEM).
In 39/44 pts a clearly defined mitral regurgitation Doppler spectrum was
obtained. RPR was reduced (<600 mmHg/s) in 23/39 pts. A negative
relation was found between RPR and circulating AM levels (r = 0.48
p = 0.02); on the contrary, no relation was found between LVEF and
circulating AM (r = 0.13, p = NS).
Thus, in pts with ICM, circulating AM levels are elevated in proportion of
the severity of contractile dysfunction as assessed by Doppler derived LV
RPR but not by LVEF. The combination of depressed RPR and increased
AM may further characterize the severity of LV dysfunction in ICM.
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Raynaud’s-syndrome is a disease of the small arteries, most commonly in
the fingers and toes. The symptoms are caused by vasospasm and occur
